scholarly journals Clinical Correlation of Cerebrospinal Fluid Total tau Levels and MMSE Score in a memory clinic

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 877-877
Author(s):  
Neil Tangal ◽  
Neeraj Tangal ◽  
Anil Nair ◽  
Malini Nair
Keyword(s):  
Cerebrospinal Fluid ◽  
Multivariate Model ◽  
Memory Clinic ◽  
Protein Levels ◽  
Total Tau ◽  
Clinic Sample ◽  
Large Memory ◽  
South Shore ◽  
Cognitive Screen ◽  
Univariate Analyses

Abstract Tau protein levels in cerebrospinal fluid are a biomarker of Alzheimer’s disease. We correlated MMSE severity to CSF tau levels in a large memory clinic sample. We retrospectively analyzed data from patients attending a memory clinic in the south shore of Boston from 2010 to 2020, and had a lumbar puncture to obtain CSF Tau levels. We compiled cognitive screen data from MMSE scores. Univariate analyses used Spearman correlation as data were non-normal. A multivariate model was created including covariates of age, sex, and race. 965 patients attended the memory clinic from 2010 to 2020. 711 had available MMSE scores. 129 subjects had lumbar punctures and available CSF tau levels. Univariate analyses showed that cognition as measured by MMSE total was not correlated to total tau levels in the CSF (rho=-0.07, p>0.05), but caucasian race was inversely associated with CSF tau levels (rho= -0.217, p<0.05). In a multivariate model, tau levels in the CSF were not associated with MMSE, race, gender, or age. In a large memory clinic sample, CSF tau levels did not correlate to MMSE scores, age, race or gender.

scholarly journals Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

Neurology ◽  
2011 ◽  
Vol 78 (1) ◽  
pp. 47-54 ◽  
Author(s):  
N. S. M. Schoonenboom ◽  
F. E. Reesink ◽  
N. A. Verwey ◽  
M. I. Kester ◽  
C. E. Teunissen ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Memory Clinic ◽  
Dementia Diagnosis ◽  
Large Memory

scholarly journals Does Anxiety Affect the Clock-Drawing Task in Patients in a Memory Clinic? A Clinical Correlation Study

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 284-284
Author(s):  
Hamed Khachan ◽  
Mahak Kanjolia ◽  
Anil Nair
Keyword(s):  
Female Gender ◽  
Correlation Study ◽  
Memory Clinic ◽  
Positive Correlation ◽  
Clock Drawing Test ◽  
Clock Drawing ◽  
Drawing Task ◽  
South Shore ◽  
Anxiety Levels ◽  
Univariate Analyses

Abstract Background: It is unknown if anxiety levels affect performance on clock drawing test (CDT) in memory clinic patients. Method: We performed a retrospective analysis of memory clinic patients in the south shore of Boston from 2010 to 2019. We correlated anxiety screen data (GAD7) to CDT scores, based on contour, numbers, and hands placement. Univariate analyses used Spearman correlation. A multivariate regression model analzed GAD7 to covariates of CDT, age, sex, and race. Hypothesis : We hypothesized a positive correlation between anxiety levels scored by the GAD7 and CDT. Results: 994 patients in the memory clinic between 2010-2020 had analyzable data. Patients were 58.6% female, 84.6 % White. Mean age was 70.1±14.4, CDT 1.84±1.04. CDT score correlated significantly to race (⍴=-0.16, p< 0.001), age (⍴=-0.28, p<0.001), gender (⍴=0.05, p=0.16), but not GAD7 (⍴=0.05, p=0.27). Multivariate model confirmed the lack of association of anxiety scores to CDT (□= 0.08, p=0.78). GAD7 scores correlated to female gender (□= -1.16, p=0.04). Conclusions: CDT scores were not affected by anxiety as measured on GAD7 scores. However, a positive correlation was shown on anxiety scores in females to CDT completion.

scholarly journals Is Immediate Recall test scores affected by Anxiety in a memory clinic population? A clinical correlation study

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 284-285
Author(s):  
Hamed Khachan ◽  
Anil Nair ◽  
Fioralba Andrea ◽  
Mahak Kanjolia
Keyword(s):  
Regression Model ◽  
Task Performance ◽  
Univariate Analysis ◽  
Correlation Study ◽  
Memory Clinic ◽  
Immediate Recall ◽  
South Shore ◽  
And Gender ◽  
Clinic Population ◽  
Univariate Analyses

Abstract Background: It is unknown if anxiety affects performance on immediate recall testing (IR) in memory clinic patients. Method: We performed a retrospective analysis of memory clinic patients in the south shore of Boston from 2010 to 2019. We correlated anxiety screen data (GAD7) to IR scores. Univariate analyses used Spearman correlation. A multivariate regression model analyzed GAD7 to covariates of IR, age, sex, and race. Hypothesis: We hypothesized a positive correlation between anxiety levels scored by GAD7 and IR. Results: 994 patients in the memory clinic between 2010-2020 had analyzable data. Patients were 58.6% female, 84.6 % White. The mean age was 70.1±14.4, IR 6.62 ± 5.4, GAD7 5.5±5.71. On univariate analysis, IR correlated significantly to age (⍴ = 0.08, p = 0.01), gender (⍴ = 0.06, p = 0.046), and race (⍴= - 0.25, p <0.001), but not to GAD7 (⍴=-0.07, p=0.14). The multivariate model confirmed the lack of association of anxiety scores to (□=-0.05, p=0.41) to GAD7 scores. IR task performance was significantly associated only to age (□= -0.04, p=0.03) and gender (□= -1.18, p=0.04) in the regression model. Conclusions: Immediate recall task performance was not significantly affected by anxiety measured by GAD7 scores in a memory clinic population. However, a negative correlation was shown on immediate recall scores in males and older subjects.

Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis

2007 ◽  
Vol 115 (5) ◽  
pp. 325-330 ◽  
Author(s):  
M. Terzi ◽  
A. Birinci ◽  
E. Çetinkaya ◽  
M. K. Onar
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Tau Protein ◽  
Protein Levels ◽  
Total Tau

scholarly journals Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population

2017 ◽  
Vol 9 (1) ◽  
Author(s):  
Daniela Bertens ◽  
Betty M. Tijms ◽  
Philip Scheltens ◽  
Charlotte E. Teunissen ◽  
Pieter Jelle Visser
Keyword(s):  
Cerebrospinal Fluid ◽  
Memory Clinic ◽  
Large Memory ◽  
Unbiased Estimates ◽  
Β Amyloid ◽  
Clinic Population

Increased levels of total tau protein in the cerebrospinal fluid in Huntington’s disease

2011 ◽  
Vol 17 (9) ◽  
pp. 714-715 ◽  
Author(s):  
Radu Constantinescu ◽  
Megan Romer ◽  
Henrik Zetterberg ◽  
Lars Rosengren ◽  
Karl Kieburtz
Keyword(s):  
Cerebrospinal Fluid ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Tau Protein ◽  
Total Tau

scholarly journals On the design of early-phase Alzheimer’s disease clinical trials with cerebrospinal fluid tau outcomes

2021 ◽  
pp. 174077452110344
Author(s):  
Michelle M Nuño ◽  
Joshua D Grill ◽  
Daniel L Gillen ◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Cerebrospinal Fluid ◽  
Phosphorylated Tau ◽  
Inclusion Criteria ◽  
Eligibility Criteria ◽  
Total Tau ◽  
Prodromal Alzheimer’S Disease ◽  
Study Power

Background/Aims: The focus of Alzheimer’s disease studies has shifted to earlier disease stages, including mild cognitive impairment. Biomarker inclusion criteria are often incorporated into mild cognitive impairment clinical trials to identify individuals with “prodromal Alzheimer’s disease” to ensure appropriate drug targets and enrich for participants likely to develop Alzheimer’s disease dementia. The use of these eligibility criteria may affect study power. Methods: We investigated outcome variability and study power in the setting of proof-of-concept prodromal Alzheimer’s disease trials that incorporate cerebrospinal fluid levels of total tau (t-tau) and phosphorylated (p-tau) as primary outcomes and how differing biomarker inclusion criteria affect power. We used data from the Alzheimer’s Disease Neuroimaging Initiative to model trial scenarios and to estimate the variance and within-subject correlation of total and phosphorylated tau. These estimates were then used to investigate the differences in study power for trials considering these two surrogate outcomes. Results: Patient characteristics were similar for all eligibility criteria. The lowest outcome variance and highest within-subject correlation were obtained when phosphorylated tau was used as an eligibility criterion, compared to amyloid beta or total tau, regardless of whether total tau or phosphorylated tau were used as primary outcomes. Power increased when eligibility criteria were broadened to allow for enrollment of subjects with either low amyloid beta or high phosphorylated tau. Conclusion: Specific biomarker inclusion criteria may impact statistical power in trials using total tau or phosphorylated tau as the primary outcome. In concert with other important considerations such as treatment target and population of clinical interest, these results may have implications to the integrity and efficiency of prodromal Alzheimer’s disease trial designs.

Sign in / Sign up

Export Citation Format

Share Document